Significance of Multimodality Therapy in Patients with a Superior Sulcus Tumor of the Lung: A Review Article

Gouji Toyokawa, Mitsuhiro Takenoyama, Yukito Ichinose

Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.
Email: yichinos@nk-cc.go.jp

Received December 20th, 2013; revised January 10th, 2014; accepted January 17th, 2014

Copyright © 2014 Gouji Toyokawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In accordance of the Creative Commons Attribution License all Copyrights © 2014 are reserved for SCIRP and the owner of the intellectual property Gouji Toyokawa et al. All Copyright © 2014 are guarded by law and by SCIRP as a guardian.

ABSTRACT

Despite the aggressive pursuit of diagnostic and treatment modalities for lung cancer, the treatment outcomes are still not satisfactory, and even patients with surgically resectable non-small cell lung cancer (NSCLC) are often at considerable risk of suffering recurrence and/or death from lung cancer. Regarding the treatment of patients with locally advanced, resectable NSCLC, several retrospective and prospective studies have shown the significance of multimodality treatments with preoperative chemoradiotherapy and surgical treatment. However, no definitive treatment strategies for locally advanced NSCLC patients have yet been established. One of the reasons for the lack of established treatment strategies for patients with locally advanced NSCLC is considered to be the heterogeneity of the population, i.e., cT4N0, cT3-4N1 and cT1a-3N2 tumors are included in stage IIIA disease, and superior sulcus tumors (SSTs) are also included in this classification. With regard to SST, two representative prospective phase II trials indicated the efficacy of surgical treatment following concurrent radiation and chemotherapy. In a study conducted by the Southwest Oncology Group, 110 patients with superior sulcus NSCLC were treated with two cycles of cisplatin and etoposide concurrently with 45 gray (Gy) of radiation, followed by surgical treatment and two additional cycles of chemotherapy postoperatively. The response rate (RR) to the preoperative chemoradiotherapy was 86%, and 83 patients (76%) were able to undergo complete resection. A pathological complete response (CR) was observed in 61 patients (56%), and the five-year survival of all patients and those undergoing complete resection was 44% and 54%, respectively. A phase II study conducted by the Japan Clinical Oncology Group examined the safety and efficacy of preoperative concurrent chemoradiotherapy using mitomycin, vinblastin and cisplatin followed by surgical treatment. Seventy-six patients with SST were enrolled in this study, and all received chemotherapy using two cycles of MVP concurrently with 45 Gy of radiation, followed by surgery. Neoadjuvant chemoradiotherapy resulted in a 61% RR, and pathological complete resection was successfully achieved in 51 patients (68%). A pathological CR was observed in 12 patients (16%), and the disease-free and overall survival rates at five years were 45% and 56%, respectively. Both studies showed the efficacy and tolerability of the multimodality treatment for SST, thus suggesting that multimodality treatment with preoperative chemoradiotherapy followed by surgery may therefore be an effective treatment for resectable SST. We herein review the results of retrospective and prospective studies while assessing the treatment outcomes of NSCLC patients with SST.

KEYWORDS
Locally Advanced Non-Small Cell Lung Cancer; Superior Sulcus Tumor; Multimodality Therapy

1. Introduction

Lung cancer is the leading cause of cancer death in many developed countries including Japan [1]. Despite the aggressive pursuit of both diagnostic and treatment modalities for lung cancer, the treatment outcomes for lung cancer still remain unsatisfactory, and even patients with surgically resectable non-small cell lung cancer (NSCLC) are at considerable risk of both recurrence and death from lung cancer. When treating patients with lung can-
cancer, it is therefore crucial to comprehensively understand the patient background, the exact stage of the tumor, the histological subtype and the molecular pathogenesis of the lung cancer. The recommended treatment strategies vary according to the stage of lung cancer. Complete resection of one lobe or more, in which the lesion is located, is recommended for patients with stage I-II disease [2-5], and some populations with these stages have been shown to benefit from adjuvant chemotherapy, including platinum-based chemotherapy or uracil and tegafur (also referred to as UFT) [6-8]. Patients with stage IV disease are mainly treated by chemotherapy [9], while palliative treatment, such as irradiation for metastasized bone or brain lesions is optionally administered. For this population, treatment strategies based on the mutation status of oncogenic drivers, such as the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and so on, are critical, because those harboring the mutations of these genes benefit from treatment with specific kinase inhibitors [10-12]. Regarding the treatment of patients with locally advanced, i.e., stage III, NSCLC, surgical treatment alone has been shown to be insufficient for the control of both local and distant disease [13-16]. Although several reports have indicated the efficacy and safety of concurrent chemotherapy and radiation followed by surgery, the treatment of patients with locally advanced NSCLC still remains controversial. Superior sulcus tumors (SSTs) are included in locally advanced NSCLC, and multimodality treatment with preoperative chemoradiotherapy followed by surgical resection is currently a standard treatment strategy for resectable SST.

We herein review the results of both retrospective and prospective studies analyzing the outcomes of the multimodality treatment for NSCLC patients with SST. Although the surgical techniques for SST are very challenging and several approaches have been developed [17-21], these technical aspects are not evaluated in this review article.

2. Evidence for the Treatment of SST

2.1. Definition of SST as a Surgical Subject

SSTs are bronchogenic cancers that typically produce unremitting pain in the distribution of the eighth cervical and first and second thoracic nerve roots, and are also associated with Horner’s syndrome and motor deficits of the intrinsic hand muscles (known as Pancoast’s syndrome). The apical location of the tumor is associated with its tendency to cause severe pain, and functional deficits are caused by its locally invasive nature. Paulson et al. introduced an approach involving neoadjuvant radiotherapy followed by surgical resection, and this approach became the standard model from 1975 to 1997 [22]. Rusch et al. reviewed retrospective studies which analyzed the treatment outcomes for superior pulmonary cancer, and showed that the survival at five years ranges from 25% to 30% [23]. In studies other than that reported by Martinez-Monge et al. [24], radiotherapy alone was followed by surgery. The percentage of patients able to undergo a complete resection ranged from 48% to 76%, and the combined treatment modality led to a two-year survival ranging from 34% to 64% and a five-year survival ranging from 17.4% to 56%. Among the studies reviewed by Rusch et al., only the study conducted by Martinez-Monge et al. employed concurrent chemoradiotherapy (MVP: mitomycin, vinblastin and cisplatin) followed by surgical treatment; however, the survival benefit of this multidisciplinary therapy was not observed in comparison to other studies. As a matter of course, much care should be taken when interpreting these data, since the findings were obtained from retrospective studies that were carried out on a small number of patients. In addition, beginning in the late 1990s, several investigators conducted retrospective studies on the treatment for SST [23-32]. In addition, three prospective trials conducted by Marra et al., the Southwest Oncology Group (SWOG) and the Japan Clinical Oncology Group (JCOG) investigated the feasibility of surgery following neoadjuvant concurrent chemoradiotherapy for patients with SST [33-36].

The question thus arises, are SSTs truly indicated for surgery? Although performing surgical resection has long been considered impossible due to the unique anatomical location of SST, the development of multimodality treatment and novel techniques, as mentioned above, thus makes this challenging subset of lung cancer amenable to potential curative treatment [37]. Several retrospective studies have demonstrated the safety and efficacy of extended surgical resection in cases of SST. For instance, according to a report by the M.D. Anderson Cancer Center, patients with SST invading the vertebrae were safely and effectively treated with a multidisciplinary surgical approach, including total vertebrectomy, partial vertebrectomy and either neural foramina or transverse process resection [26]. In two representative studies conducted by the SWOG and JCOG, SST patients with invasion to the chest wall or subclavian vessels (T3) and spine, aorta or superior vena cava (T4) were included in the analyses. According to the JCOG study, although hilar nodal (N1) and/or ipsilateral nodal (N3) involvement was judged to be eligible, SSTs with mediastinal nodal involvement (N2) were not included [36]; only hilar nodal metastasis was included in the SWOG study [34,35]. Combined resection of the invaded adjacent structures, as indicated above, was achieved without any
severe surgery-related complications. Importantly, multimodality treatment with concurrent chemoradiotherapy followed by surgery achieved better outcomes than those observed in the retrospective studies. Based on these findings, SST lesions invading the surrounding vital structures and/or with metastasis to the hilar or supraclavicular lymph nodes are thus considered to be indicated for surgery.

2.2. Results of Retrospective Studies

Table 1 shows the clinical outcomes of the seven representative retrospective trials performed since the early 1990s. According to these studies, although the clinicopathological characteristics of the enrolled population, such as the number, stage and treatment modalities were heterogeneous, the rate of complete resection and five-year survival ranged from 23% to 100%, and from 0% to 65%, respectively, which were similar to those reported in the review by Rusch et al. Additionally, the surgical mortality rate was 0% - 8.9%. According to a report by Hagan et al. [25], unresected primary disease, a low performance status, T4 stage and positive node status were all associated with a significantly poorer prognosis, whereas Komaki et al. [27] showed that the overall predictors of the five-year survival were weight loss, supraclavicular fossa or vertebral body involvement, the stage of the disease and the completion of surgical treatment. Multivariate analyses showed a significant impact of the T and N status and complete resection on survival [23]. In contrast, another study showed that the surgical approach, postoperative radiotherapy and postoperative chemotherapy did not improve the five-year survival, while preoperative radiotherapy did [28]. Furthermore, Alifano et al. showed that the completeness of resection and the absence of any associated major comorbidities had an independent positive prognostic value [29].

Regarding recently published reports [30-32], Pourel et al. described the results of concurrent cisplatin (CDDP)/etoposide (VP-16) with 3D-conformal radiotherapy (45 Gy/25 Fr.) followed by surgical resection for patients with SST [30]. Among the 107 patients included in their study, a complete resection was performed in 71 patients, and five patients (6.9%) died during the first three months postoperatively. The three-year overall survival (OS) rate was 40%, and the patients undergoing complete resection achieved a significantly higher three-year OS rate of 51% than did the patients who did not receive surgical resection. In a report by Kappers and colleagues, 39 patients with SST received combined modality treatment including surgery, and 25 patients were treated with accelerated radiation (66 Gy/24 Fr.) with concurrent daily CDDP [31]. Among the 25 patients who underwent chemoradiotherapy, 22 patients were able to undergo surgery. All resections were complete without any local recurrences, and the resected patients achieved a significantly better OS than the unresected patients. In addition, our institution reported the evolution of the treatment outcomes with multimodality treatment for NSCLC of the superior sulcus [32]. Fifty-seven patients with STS who were treated between 1982 and 2007 were retrospectively analyzed, and 47% of the patients underwent preoperative chemoradiation followed by surgery, and 53% underwent other treatments, such as surgery alone, surgery plus radiotherapy or chemoradiation. The five-year survival rates increased significantly from 42.6% (1982-1994) to 65.4% (1995-2007). Intriguingly, the five-year survival of patients who received neoadjuvant chemoradiotherapy followed by surgery (n = 27) was better than that of those who received another treatment regimen with surgery (n = 22, 64.6% versus 49.6%; p = 0.044). The complete resection rate was similar to that in other reports, and the five-year survival in patients with a complete resection after chemoradiotherapy was 70.4%. Although these were retrospective studies which analyzed only a small number of patients with SST, they nevertheless showed that multimodality treatment with preoperative chemoradiation followed by surgical resection can achieve good treatment outcomes.

2.3. Results of Prospective Studies

Only three prospective studies have so far examined the feasibility of neoadjuvant chemoradiotherapy followed by surgery for patients with SST (Table 2). Marra and associates conducted a prospective feasibility study to determine whether multimodality treatment improves the local control and survival [33]. Thirty-one patients with SST (T3: 81%; T4: 19%) were enrolled in the study, and all of the patients could receive the induction chemotherapy with three courses of split-dose CDDP and VP-16 or paclitaxel, followed by concurrent chemoradiotherapy with a course of CDDP/VP-16 with concurrent 45 Gy hyperfractionated accelerated radiation. Twenty-nine (94%) patients were eligible for surgical resection, and a complete resection was achieved in 94% of these patients, with a thirty-day mortality rate of 6.4%. Forty-eight percent of the patients achieved a partial response with induction treatment, and a pathological complete response (CR) was observed in 13 (4.9%) patients. The actual OS at five years for the entire population was 46%, with a median survival of 54 months. The five-year OS rates were 63% for the complete responders versus 35% for the partial responders (p = 0.10); patients receiving paclitaxel-based induction therapy had a higher five-year OS rate compared with the patients treated with VP-16 (76% versus 31%; p = 0.16). Recurrences were observed
### Table 1. The results of retrospective series of patients with SST treated with multimodality treatments since the early 1990s.

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Total number of patients</th>
<th>Percentage of resected patients</th>
<th>Stage (IIB IIA IIB IV)</th>
<th>Preoperative treatment</th>
<th>Postoperative treatment</th>
<th>Percent having complete resection (%)</th>
<th>Dose of radiation (Gy)</th>
<th>Regimen of chemotherapy</th>
<th>5-year survival (%)</th>
<th>Surgical mortality (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Komaki et al. [27] (2000)</td>
<td>143</td>
<td>62</td>
<td>36 (28) 31 (11) 76 (23) 0 (0)</td>
<td>CTx + RTx: 12“</td>
<td>RTx + CTx: 28“</td>
<td>55</td>
<td>50 - 64</td>
<td>not described</td>
<td>not described</td>
<td>not described</td>
</tr>
<tr>
<td>Rusch et al. [23] (2000)</td>
<td>225</td>
<td>225</td>
<td>117 33 61 8</td>
<td>RTx: 101; CTx: 23; CRTx: 22</td>
<td>not described</td>
<td>56</td>
<td>400 - 8000 cGy</td>
<td>not described</td>
<td>IIB: 46; IIA: 0; IIB: 13</td>
<td>4</td>
</tr>
<tr>
<td>Martinod et al. [28] (2002)</td>
<td>139</td>
<td>139</td>
<td>71 19 45 4</td>
<td>RTx: 24; CTx: 5; CRTx: 12</td>
<td>RTx: 58; CTx: 3; CRTx: 32</td>
<td>81</td>
<td>30</td>
<td>not described</td>
<td>35</td>
<td>7.2</td>
</tr>
<tr>
<td>Alifano et al. [29] (2003)</td>
<td>67</td>
<td>67</td>
<td>49 12 6 0</td>
<td>CTx: 3; CRTx: 4</td>
<td>RTx: 42; CTx: 2; CRTx: 9</td>
<td>45</td>
<td>10 - 50</td>
<td>not described</td>
<td>36</td>
<td>8.9</td>
</tr>
<tr>
<td>Pourel et al. [30] (2008)</td>
<td>107</td>
<td>105</td>
<td>18 (18) 58 (57) 31 (30) 0</td>
<td>CRTx (3D-conformal RTx)</td>
<td>RTx + CTx: 10; CTx: 8</td>
<td>68</td>
<td>45</td>
<td>CDDP + VP-16</td>
<td>40 (3-year survival)</td>
<td>3</td>
</tr>
<tr>
<td>Kappers et al. [31] (2009)</td>
<td>85</td>
<td>22</td>
<td>25 (N/A) 7 (N/A) 32 (N/A) 21 (N/A)</td>
<td>CRTx (accelerated RTx)</td>
<td>None</td>
<td>100</td>
<td>66</td>
<td>Low-dose CDDP</td>
<td>37</td>
<td>0</td>
</tr>
<tr>
<td>Tagawa et al. [32] (2010)</td>
<td>57</td>
<td>44</td>
<td>25 (N/A) 10 (N/A) 22 (N/A) 0 (0)</td>
<td>CRTx: 27</td>
<td>RTx: 6</td>
<td>75</td>
<td>40 - 60</td>
<td>Platinum-based doublet or triplet</td>
<td>43 (1982-1994) or 65 (1995-2007)</td>
<td>2</td>
</tr>
</tbody>
</table>

1 Number of resected patients. 2 Seventeen patients received preop and postop radiotherapy + chemotherapy. RTx: radiotherapy; CRTx: chemoradiotherapy; CTx: chemotherapy. N/A: not available.

### Table 2. Treatment outcomes of prospective studies investigating multimodality treatment for superior sulcus tumor.

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Total number of patients</th>
<th>Number of resected patients</th>
<th>T factor*</th>
<th>Preoperative treatment</th>
<th>Postoperative treatment</th>
<th>Percent having complete resection (%)</th>
<th>Dose of radiation (Gy)</th>
<th>Regimen of chemotherapy</th>
<th>5-year survival (%)</th>
<th>Surgical mortality (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marra et al. [33] (2007)</td>
<td>31</td>
<td>29</td>
<td>25 6</td>
<td>CTx → CRTx</td>
<td>No</td>
<td>100</td>
<td>45 (hyperfractionated accelerated RTx)</td>
<td>CDDP + PTX (71%) or CDDP + VP-16 (29%)</td>
<td>46</td>
<td>6.4</td>
</tr>
<tr>
<td>Rusch et al. [34,35] (2007)</td>
<td>110</td>
<td>88</td>
<td>78 32</td>
<td>CRTx</td>
<td>Consolidation CTx</td>
<td>76</td>
<td>45</td>
<td>CDDP + VP-16</td>
<td>44</td>
<td>1.8</td>
</tr>
<tr>
<td>Kunimoto et al. [36] (2008)</td>
<td>76</td>
<td>57</td>
<td>56 20</td>
<td>CRTx</td>
<td>Boost RTx for unresected or incompletely resected cases (21.6 Gy)</td>
<td>68</td>
<td>45</td>
<td>MVP</td>
<td>56</td>
<td>1.8</td>
</tr>
</tbody>
</table>

*The detailed T factors of resected patients were not described. RTx: radiotherapy; CRTx: chemoradiotherapy; CTx: chemotherapy. CDDP: cisplatin; VP-16: etoposide; MVP: mitomycin + vindesine + cisplatin.
as 11 events in nine (29%) patients: one (3.2%) patient suffered a local recurrence, seven (22.6%) patients suffered distant metastases (the most common site was the brain: 12.9%) and one (3.2%) patient suffered both at the same time.

A prospective phase II study was conducted by the SWOG to evaluate the safety and efficacy of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus NSCLC [34,35]. One hundred and ten patients with T3-4, N0-1 SST were enrolled in SWOG 9416 (Intergroup Trial 0160) from April 1995 to November 1999, and they were treated with two cycles of CDDP and VP-16 concurrently with 45 Gy of radiation. Eighty-eight patients (80%) could undergo surgical resection and two additional cycles of chemotherapy postoperatively. The response rate (RR) to the preoperative chemoradiotherapy was 86%, and 83 patients (76%) had a complete resection. A pathological CR was observed in 61 patients (56%), and the five-year survival of all patients and those undergoing complete resection were 44% and 54%, respectively. Although the T stage had no impact on the survival, a pathological CR was associated with a prolonged survival compared with those without a pathological CR. Additionally, induction therapy was shown to be well tolerated, and postoperative pulmonary complications were the most common complication, with pneumonia occurring in 13.6% of patients, and postoperative death occurred in two patients (2.3%) due to multisystem failure. Although local recurrence developed in only 10 patients, disease progression occurred mainly at distant sites, and the most common single site was the brain, with recurrence in this site in 19 of 57 patients.

The JCOG prospectively examined the safety and efficacy of preoperative concurrent chemoradiotherapy using MVP followed by surgical treatment [36]. From 1999 to 2002, 76 patients with SST were enrolled in the JCOG 9806 trial, and they received chemotherapy with two cycles of MVP concurrently with 45 Gy of radiation, followed by surgery. Fifty and 20 patients had T3 and T4 disease, respectively, and fifty-seven patients (76%) underwent surgical resection, with a pathological complete resection achieved in 51 patients (68%). Neoadjuvant chemoradiotherapy resulted in a 61% RR, and a pathological CR was observed in 12 patients. The disease-free and OS rates at five years were 45% and 56%, respectively. The clinical T stage was proven to be a prognostic factor, and patients with clinical T3 disease had a better outcome than those with clinical T4 disease, i.e., the survival rates at five years were 61% versus 40%. Consistent with the results of the SWOG 9416, the survival of the 12 patients with a pathological CR was especially favorable compared with that of the patients who did not experience a pathological CR. Although more than 80% of the patients experienced neutropenia/leukopenia, chemoradiotherapy was reported to be generally well tolerated. The major postoperative morbidities included adult respiratory distress syndrome (ARDS) in two patients, empyema in two patients, chylothorax in two patients, and pneumonitis in two patients, and the total number of toxic deaths was three, including one caused by septic shock during the induction, one by delayed postoperative bleeding, and one by the development of ARDS after off-protocol, salvage surgery. For completely resected cases, relapse at distant sites was the most frequent relapse pattern, while locoregional relapse was predominant in unresected or incompletely resected cases.

One possible concern, as observed in both the JCOG and SWOG studies, is the management of patients with metastasis to the mediastinal nodes (N2). As indicated above, the JCOG study excluded patients with N2 disease, and N2 regions (as well as N1 regions, even if involved) were not included in the irradiation field. Since the data obtained by the JCOG showed an increase in toxicity associated with the inclusion of N1 and N2 disease in the irradiation field [38] and clinical N2 disease has been shown to be the poorest prognostic factor [23], these exclusion criteria appear to be reasonable. Furthermore, to not irradiate N2 disease is considered to be beneficial when conducting surgical resection of both the upper lobe in which the tumor is located and the invaded adjacent structures, such as vertebrae. Therefore, when treating SSTs associated with clinical N2 disease, obtaining a pretreatment diagnosis is essential. In addition, the recent development of less invasive diagnostic methods, such as endobronchial ultrasound-guided transbronchial needle aspiration, is considered to improve the diagnostic process [39].

Although the regimens of chemotherapy used in the two representative prospective studies were not third-generation [34-36], the five-year survival rates of the two prospective trials were superior to those of historical controls, i.e., 44% and 56%. Based on these findings, surgical treatment following concurrent chemoradiotherapy is considered to be a standard treatment for patients with resectable superior sulcus NSCLC.

With regard to postoperative chemoradiotherapy, there was one prospective phase II trial conducted by Gomez et al. [40]. From 1994 to 2010, 32 patients with SST were enrolled in the study, and they were treated with surgical treatment followed by concurrent chemoradiotherapy using CDDP + VP-16 (60 Gy if the surgical margins were negative; 64.8 Gy if the margins were positive). Complete resection was possible in 23 patients (72%), and the surgical mortality was 0%. Although the
five-year disease-free survival and OS rates were 45% and 50%, respectively, which were comparable to those of the SWOG and JCOG studies, there were some critical problems in that study: the criteria for surgical treatment were unclear, the inclusion period was too long and the number of cases enrolled in the study was small. Therefore, for the present, adjuvant concurrent chemoradiotherapy after surgical treatment is not recommended for patients with SST.

3. Future Challenges

Although the treatment outcomes reported by the SWOG and JCOG were sufficiently successful to recommend concurrent chemoradiation followed by surgical resection [34-36], it is likely that there is still room for improvement in treatment outcomes for SST. One of factors for such possible improvement is assumed to be the identification of which chemotherapeutic regimen should be combined with radiotherapy. Although the chemotherapeutic drugs used in studies by the SWOG and JCOG included radiosensitizing drugs, they were not third-generation chemotherapeutic agents. Apart from SST, a phase III study was performed by the West Japan Thoracic Oncology Group to compare the second- and third-generation chemotherapeutic regimens concurrently used with radiotherapy (60 Gy) in patients with unresectable stage III NSCLC [41]. Although no significant differences in the OS were observed between second- (mitomycin/vindesine/CDDP) and third-generation (irinotecan/carboplatin or paclitaxel/carboplatin) regimens, the third-generation regimens with paclitaxel/carboplatin achieved a more favorable toxicity profile in comparison to other regimens, thus leading to the conclusion that the regimen with paclitaxel/carboplatin should be considered as the standard regimen for the treatment of locally advanced unresectable NSCLC. Furthermore, Ichinose et al. reported excellent outcomes for a prospective phase II study that examined the efficacy and safety of the treatment with S-1 plus CDDP with concurrent radiotherapy (60 Gy) for patients with locally advanced NSCLC [42]: an objective response rate was achieved in 84% of the 50 evaluable patients; the one- and two-year OS rates were 88% and 70%, respectively, and the median PFS was 20 months, which was better than that reported by Yamamoto et al. (paclitaxel/carboplatin: 9.5 months) [41]; the toxicity profile was acceptable. The efficacy and safety of the treatment using S-1/CDDP with concurrent radiotherapy was also confirmed for resectable patients with stage III NSCLC [43]. Based on these data, the regimen of S-1/CDDP used concurrently with radiation might also be also promising for patients with SST, and should be prospectively investigated for its safety and efficacy.

Another concern to be solved is a high rate of distant relapse after surgical resection. The distant relapse rates, especially recurrence in the brain, are higher than the locoregional relapse rates. With regard to the control of brain metastases after multimodality treatment for locally advanced NSCLC (not SST), a phase III prospective study was conducted to compare prophylactic cranial irradiation (PCI) versus observation after the multimodality treatment [47]. PCI decreased the incidence of brain metastasis; however, neither the OS nor DFS improved. The authors concluded that PCI is not recommended, since there was no evidence of a survival benefit in patients with locally advanced NSCLC. The fact that the control of brain metastasis failed to improve the patient survival led to the idea to examine the use of intensive neoadjuvant and/or adjuvant chemotherapy after surgical resection. The administration of molecular targeted therapy, such as EGFR-TKI and ALK inhibitors [10-12], for patients with SST in the neoadjuvant and/or adjuvant setting might be promising, which should be
clarified by prospective studies, although the molecular and genetic profiling of SST has yet to be performed. For instance, Okamoto et al. conducted a feasibility study to examine the safety and toxicity profile of daily gefitinib treatment concurrently administered with thoracic radiation in patients with unresectable, locally advanced NSCLC [48]. Although the study was closed because of the lower rate of treatment completion than expected before the study initiation, and only two patients harbored sensitive EGFR mutations, both of these two patients completed the designed treatment schedule and exhibited an OS greater than five years. It is difficult to conclude whether concurrent gefitinib treatment with radiotherapy is safe and effective for locally advanced NSCLC based on these two cases; however, this therapeutic strategy might hold promise. These results might therefore be applicable for patients with SST, which is a very small subset of NSCLC.

4. Conclusion

We herein reviewed both representative retrospective and prospective studies of the treatment modalities, especially induction therapy followed by surgery, for patients with SST. At present, induction treatment with preoperative chemoradiation followed by surgery, appears to be a potent treatment option for patients with resectable SST, and future studies are warranted to improve the survival rates, as well as the control of both local and distant relapse, especially in the brain.

Acknowledgements

None of the authors have any conflicts of interest to declare. We thank Brian Quinn, Editor-in-Chief, Japan Medical Communication, for providing critical comments on the manuscript.

REFERENCES


Significance of Multimodality Therapy in Patients with a Superior Sulcus Tumor of the Lung: A Review Article


[41] N. Yamamoto, et al., “Phase III Study Comparing Second- and Third-Generation Regimens with Concurrent Thoracic Radiotherapy in Patients with Unresectable...
Significance of Multimodality Therapy in Patients with a Superior Sulcus Tumor of the Lung: A Review Article


